These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35190544)

  • 1. Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.
    Stocchi F; Antonini A; Berg D; Bergmans B; Jost W; Katzenschlager R; Kulisevsky J; Odin P; Valldeoriola F; Ray Chaudhuri K
    NPJ Parkinsons Dis; 2022 Feb; 8(1):17. PubMed ID: 35190544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Spanish Consensus on the Use of Safinamide for Parkinson's Disease in Clinical Practice.
    Pagonabarraga J; Arbelo JM; Grandas F; Luquin MR; Martínez Martín P; Rodríguez-Oroz MC; Valldeoriola F; Kulisevsky J
    Brain Sci; 2020 Mar; 10(3):. PubMed ID: 32197462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey.
    Takeda A; Tsuboi Y; Nomoto M; Mochizuki H; Hattori N
    Parkinsons Dis; 2022; 2022():3203212. PubMed ID: 35873701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real world data of a German Parkinson's disease population: effectiveness and safety of safinamide in routine clinical practice.
    Jost WH; Gluth I; Lück JC; Lopes OIFDC;
    Curr Med Res Opin; 2023 Dec; 39(12):1621-1628. PubMed ID: 37421634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.
    Espinoza-Vinces C; Villino-Rodríguez R; Atorrasagasti-Villar A; Martí-Andrés G; Luquin MR
    Patient Relat Outcome Meas; 2023; 14():285-295. PubMed ID: 37840836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2018 Jul; ():. PubMed ID: 30072274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.
    De Masi C; Liguori C; Spanetta M; Fernandes M; Cerroni R; Garasto E; Pierantozzi M; Mercuri NB; Stefani A
    J Neural Transm (Vienna); 2022 Nov; 129(11):1331-1338. PubMed ID: 36070008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of safinamide on pain in patients with fluctuating Parkinson's disease.
    Grigoriou S; Martínez-Martín P; Ray Chaudhuri K; Rukavina K; Leta V; Hausbrand D; Falkenburger B; Odin P; Reichmann H
    Brain Behav; 2021 Oct; 11(10):e2336. PubMed ID: 34478245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Valldeoriola F; Grandas F; Arbelo JM; Blázquez Estrada M; Calopa Garriga M; Campos-Arillo VM; Garcia Ruiz PJ; Gómez Esteban JC; Leiva Santana C; Martínez Castrillo JC; Mir P; Salvador Aliaga A; Vivancos Matellano F; Yáñez Baña RM
    Neurologia (Engl Ed); 2021; 36(9):666-672. PubMed ID: 34752344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for parkinson's disease.
    Kurihara K; Mishima T; Fujioka S; Tsuboi Y
    Expert Opin Drug Saf; 2022 Feb; 21(2):137-147. PubMed ID: 34597253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease.
    Abbruzzese G; Barone P; Lopiano L; Stocchi F
    Drug Des Devel Ther; 2021; 15():2507-2517. PubMed ID: 34140766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson's disease patients: a prospective longitudinal study.
    De Micco R; Satolli S; Siciliano M; De Mase A; Giordano A; Tedeschi G; Tessitore A
    Neurol Sci; 2022 Jan; 43(1):357-364. PubMed ID: 34031800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Safinamide and Gender Differences During Routine Clinical Practice.
    Pellecchia MT; Picillo M; Russillo MC; De Pandis MF; Bonizzoni E; Marjanovic I; Cattaneo C
    Front Neurol; 2021; 12():756304. PubMed ID: 34970207
    [No Abstract]   [Full Text] [Related]  

  • 17. Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
    Santos García D; Labandeira Guerra C; Yáñez Baña R; Cimas Hernando MI; Cabo López I; Paz Gonález JM; Alonso Losada MG; González Palmás MJ; Martínez Miró C
    Brain Sci; 2021 Mar; 11(3):. PubMed ID: 33801565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease.
    Rizzone MG; Mancini F; Artusi CA; Balestrino R; Bonvegna S; Fabbri M; Imbalzano G; Montanaro E; Romagnolo A; Zibetti M; Lopiano L
    Neurol Sci; 2022 May; 43(5):3187-3193. PubMed ID: 34982297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of safinamide on pain in Parkinson's disease with motor fluctuations: an exploratory study.
    Geroin C; Di Vico IA; Squintani G; Segatti A; Bovi T; Tinazzi M
    J Neural Transm (Vienna); 2020 Aug; 127(8):1143-1152. PubMed ID: 32572581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.
    Fabbri M; Rosa MM; Abreu D; Ferreira JJ
    Neurodegener Dis Manag; 2015 Dec; 5(6):481-96. PubMed ID: 26587996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.